Clinical trials
Recruiting Prostatic Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
485 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 10 |
| 2019 | 13 |
| 2020 | 12 |
| 2021 | 36 |
| 2022 | 26 |
| 2023 | 57 |
| 2024 | 86 |
| 2025 | 117 |
| 2026 | 99 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 485 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 21 |
| M.D. Anderson Cancer Center | 17 |
| Mayo Clinic | 17 |
| Memorial Sloan Kettering Cancer Center | 15 |
| Jonsson Comprehensive Cancer Center | 14 |
| AstraZeneca | 11 |
| City of Hope Medical Center | 11 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 10 |
| Dana-Farber Cancer Institute | 8 |
| NYU Langone Health | 8 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 485 |
| Breast Neoplasms | 58 |
| Lung Neoplasms | 33 |
| Ovarian Neoplasms | 33 |
| Colorectal Neoplasms | 31 |
| Neoplasms | 29 |
| Pancreatic Neoplasms | 29 |
| Neoplasm Metastasis | 20 |
| Esophageal Neoplasms | 18 |
| Head and Neck Neoplasms | 18 |
Trials
Showing 1 to 25 of 485. Each trial links to its page on Pharma Observatory.
385 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.